Document:

<PAGE>   1
                                                                   EXHIBIT 10.4

                              XCYTE THERAPIES, INC.

                      SECOND ADDENDUM TO SERIES D PREFERRED
                            STOCK PURCHASE AGREEMENT

        This Second Addendum to Series D Preferred Stock Purchase Agreement (the
"Second Addendum") is made as of the 14th day of August, 2000 by and among Xcyte
Therapies, Inc., a Delaware corporation (the "Company"), the investors listed on
Exhibit A attached hereto (each an "Additional Purchaser" and together the
"Additional Purchasers"), and the existing holders of Series D Preferred Stock
listed on Exhibit B hereto (each an "Initial Series D Investor," together the
"Initial Series D Investors"). All capitalized terms not defined herein shall
have the meaning set forth in the Purchase Agreement (defined herein).

                                    RECITALS

        WHEREAS, on May 25, 2000, the Company entered into a Series D Preferred
Stock Purchase Agreement, as amended by the Addendum to Series D Preferred Stock
Purchase Agreement and Omnibus Amendment to Series B Financing Agreements dated
as of August 8, 2000 (the "Purchase Agreement") with the Initial Series D
Investors. The Purchase Agreement provides in Section 1.4 thereof that
additional investors may, under conditions set forth therein, become parties to
the Purchase Agreement at any time on or before August 8, 2000;

        WHEREAS, pursuant to the terms of Section 6.8 of the Purchase Agreement,
the Purchase Agreement may be amended only with the written consent of the
Company and Initial Series D Investors holding at least a majority of the Stock
(or the Common Stock issuable upon conversion thereof);

        WHEREAS, the Company, the Additional Purchasers, the undersigned Initial
Series D Investors, constituting the holders of sufficient shares of capital
stock of the Company to amend the Purchase Agreement, desire to amend certain
terms and conditions of the Purchase Agreement;

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

                                    AGREEMENT

        In consideration of the mutual promises, covenants and conditions
hereinafter set forth, the parties hereto mutually agree as follows:

        1.     AUTHORIZATION AND SALE OF PREFERRED STOCK AND WARRANTS.

               1.1 AUTHORIZATION OF PREFERRED STOCK. The Company has authorized
the issuance pursuant to this Second Addendum of up to 719,425 shares of its
Series D Preferred Stock (the "Additional Shares") and the issuance of Warrants
to purchase 80,575 shares of Common Stock (the "Warrants") to the Additional
Purchasers. The rights, preferences, privileges and restrictions of the Series D
Preferred Stock are as set forth in the Company's

                                      -1-

<PAGE>   2

Amended and Restated Certificate of Incorporation attached as Exhibit C to the
Purchase Agreement (the "Restated Certificate").

               1.2 SALE OF PREFERRED STOCK AND WARRANTS. Subject to the terms
and conditions hereof, at the Closing (as defined in Section 2.1 hereof) the
Company will issue and sell to each Additional Purchaser, and each Additional
Purchaser severally agrees to purchase from the Company, that number of
Additional Shares at a cash purchase price of $2.78 per share of Series D
Preferred Stock and Warrants at a cash purchase price of $0.001 per share of
Common Stock specified opposite such Additional Purchaser's name on Exhibit A
hereto. Each of the Additional Purchasers, by their signatures hereto, shall
hereby (i) become parties to the Purchase Agreement, as amended by this Second
Addendum (ii) be considered a "Purchaser" for all purposes under the Purchase
Agreement, (iii) have all the rights and obligations of a Purchaser thereunder,
(iv) become parties to the Investors' Rights Agreement, as amended, and Voting
Agreement, as amended, (v) be considered a "Series D Investor" for all purposes
under the Investor Rights Agreement, as amended, and (vi) have all the rights
and obligations of an Investor thereunder. The Additional Shares, the Warrants
and the Common Stock issuable upon exercise of the Warrants (the "Warrant
Shares") acquired by the Additional Purchasers hereunder shall be considered
"Shares" for all purposes under the Purchase Agreement, as amended.

        2.     CLOSING; DELIVERY.

               2.1 CLOSING. The closing of the purchase and sale of the
Additional Shares and Warrants hereunder (the "Closing") shall be held at the
offices of Venture Law Group, Kirkland, Washington, at 10:00 a.m., on August 14,
2000, or at such other time and place as the Company and the Additional
Purchasers may agree.

               2.2 DELIVERY. At the Closing, the Company will deliver to each
Additional Purchaser a certificate representing the number of Additional Shares
and Warrants set forth opposite such Additional Purchaser's name on Exhibit A,
against payment of the purchase price therefor by each Additional Purchaser by
check or wire transfer to the Company.

        3.     DISCLOSURE; CAPITALIZATION.
               --------------------------

               3.1 DISCLOSURE. Each Additional Purchaser hereby acknowledges
receipt of the Purchase Agreement and the exhibits thereto. The Company affirms
to each Additional Purchaser that:

                      (i) The representations and warranties of the Company set
forth in Section 2 of the Purchase Agreement were true and accurate when made;

                      (ii) Those representations and warranties, which are
incorporated herein by this reference and made a part hereof, remain true and
accurate in all material respects as of the date hereof, except (A) for changes
resulting from the transactions contemplated in the Purchase Agreement and (B)
as set forth in the Schedule of Exceptions to Representations and Warranties
attached hereto as Exhibit D.

                                      -2-

<PAGE>   3

                      (iii) The conditions to closing set forth in Section 4 of
the Purchase Agreement and in Section 5 hereof have been satisfied, provided
that the conditions set forth in Section 4.1 of the Purchase Agreement shall
include references to changes in the Company's representations and warranties
and the Company's status, respectively, as set forth herein and in the Exhibits
attached hereto, and resulting from the consummation of the transactions
contemplated by the Purchase Agreement.

               3.2    CAPITALIZATION.  Immediately prior to the Closing, the
authorized capital of the Company shall consist of:

                      (i) Immediately prior to the Closing, the authorized
capital of the Company shall consist of: (a) 60,000,000 shares of Common Stock,
and (b) 28,909,976 shares of Preferred Stock (the "Preferred Stock"), of which
7,300,080 have been designated Series A Preferred Stock, 4,097,580 have been
designated Series B Preferred Stock, 7,212,316 have been designated Series C
Preferred Stock and 10,300,000 have been designated Series D Preferred Stock.
Immediately prior to the Closing, 5,965,234 shares of Common Stock, 6,860,512
shares of Series A Preferred Stock, warrants to purchase 439,568 shares of
Series A Preferred Stock, 3,903,080 shares of Series B Preferred Stock, and
warrants to purchase 194,500 shares of Series B Preferred Stock, 7,185,630
shares of Series C Preferred Stock, warrants to purchase 26,686 shares of Series
C Preferred Stock and 9,390,400 shares of Series D Preferred Stock will be
outstanding.

                      (ii) Except as set forth in this Agreement and the
exhibits thereto, there are no outstanding options, warrants, rights (including
conversion or preemptive rights) or agreements for the purchase or acquisition
from the Company of any shares of its capital stock except that the Company has
reserved (a) the Shares for issuance at Closing, (b) the Common Stock issuable
upon conversion of the Preferred Stock, (c) 2,500,000 shares of Common Stock
reserved for issuance pursuant to a stock option plan adopted by the Company of
which options to purchase 1,037,453 shares have been granted and remain
outstanding, with 1,374,122 shares remaining for grant (d) 898,150 shares of
Common Stock reserved for issuance to scientific founders upon the achievement
of certain milestones, (e) 157,890 shares of Common Stock reserved for issuance
to Carl June or his assignees upon the Company's acquisition of certain future
technology and (f) the Warrants to purchase 1,051,712 shares of Common Stock
issued pursuant to the Purchase Agreement, as amended.

                      (iii) Based in part upon the representations of each
Purchaser in this Second Addendum and subject to the provisions of Section 2.5
of the Purchase Agreement, the Stock (and the Common Stock issuable upon
conversion thereof) has been issued or will be issued in compliance with all
applicable federal and state securities laws.

        4. REPRESENTATIONS AND WARRANTIES OF ADDITIONAL PURCHASERS AND INITIAL
SERIES D INVESTORS. Each Additional Purchaser and Initial Series D Investor,
severally and not jointly, acknowledges that such Additional Purchaser has
reviewed the representations and warranties set forth in Section 3 of the
Purchase Agreement and agrees with the Company that such representations and
warranties, which are incorporated herein by this reference and made a part

                                      -3-

<PAGE>   4

hereof, are true and correct as of the date hereof as they relate to such
Additional Purchaser's purchase of the Additional Shares and Warrants hereunder.

        5. CONDITIONS TO ADDITIONAL PURCHASERS' OBLIGATIONS AT CLOSING. The
obligation of each Additional Purchaser to purchase the Additional Shares at the
Closing is subject to the fulfillment to such Additional Purchaser's
satisfaction at or prior to the Closing of the following conditions:

               5.1 REPRESENTATIONS AND WARRANTIES CORRECT; PERFORMANCE OF
OBLIGATIONS. The representations and warranties made by the Company in Section 3
hereof shall be true and correct when made, and shall be true and correct on the
date of the Closing with the same force and effect as if they had been made on
and as of said date, subject to changes contemplated by this Second Addendum;
and the Company shall have performed all obligations and conditions herein
required to be performed or observed by it at or prior to the Closing.

               5.2 CONSENTS AND WAIVERS. The Company shall have obtained any and
all consents and waivers necessary or appropriate for consummation of the
transactions contemplated by this Second Addendum.

               5.3 LEGAL OPINION. Upon request, each of the Additional
Purchasers will be entitled to receive from Venture Law Group, legal counsel for
the Company, a legal opinion addressed to the Additional Purchasers
substantially in the form attached hereto as Exhibit E.

        6. CONDITIONS TO COMPANY'S OBLIGATIONS AT CLOSING. The obligations of
the Company under Sections 1.1 and 1.2 of this Second Addendum are subject to
the fulfillment at or before the Closing of each of the following conditions:

               6.1 REPRESENTATIONS AND WARRANTIES. The representations and
warranties of each Additional Purchaser and Initial Series D Investor contained
in Section 4 hereof shall be true at the Closing.

               6.2 CONSENTS AND WAIVERS. The Company shall have obtained any and
all consents and waivers necessary or appropriate for the Purchasers to become
parties to the Investor Rights Agreement for the consummation of the
transactions contemplated by this Second Addendum.

        7. AMENDMENT TO STOCK PURCHASE AGREEMENT. Section 1.4 of the Purchase
Agreement is hereby amended to read in its entirety as follows:

               "1.4 Additional Closings. If the full number of Series D
        Preferred Stock of the Company is not sold at the Closing, the Company
        shall have the right, at any time prior to August 18, 2000 (the
        "Subsequent Closing Date"), to sell the remaining authorized but
        unissued shares of Series D Preferred Stock to one or more additional
        purchasers as determined by the Company, or to any Purchaser hereunder
        who wishes to acquire additional shares of Series D Preferred Stock at
        the price and on the terms set forth herein, provided that any

                                      -4-

<PAGE>   5

        such additional purchaser shall be required to execute an Second
        Addendum Agreement substantially in the form attached hereto as Exhibit
        F. Any additional purchaser so acquiring shares of Series D Preferred
        Stock shall be considered a "Purchaser" for purposes of this Agreement
        and an "Investor" for the purposes of the Agreements (as defined below),
        and any Series D Preferred Stock so acquired by such additional
        purchaser shall be considered "Shares" for purposes of this Agreement
        and all other agreements contemplated hereby."

        8.     MISCELLANEOUS.

               8.1 INCORPORATION BY REFERENCE. The provisions set forth in
Section 6 of the Purchase Agreement (other than Section 6.6) are incorporated
herein by this reference and made a part hereof. Except as otherwise set forth
herein, the terms and conditions of the Purchase Agreement shall remain in full
force and effect notwithstanding the execution of this Agreement and are
incorporated in their entirety herein and made a part of this Second Addendum as
if fully set forth herein.

               8.2 NOTICES. Any notice required or permitted by this Second
Addendum and/or the Agreements shall be in writing and shall be deemed
sufficient upon delivery, when delivered personally or sent by overnight courier
telegram or fax, or forty-eight (48) hours after being deposited in the U.S.
mail, as certified or registered mail, with postage prepaid, and addressed to
the party to be notified at such party's address or fax number (as set forth
below or in the Purchase Agreement or on Exhibit A hereto or thereto, or as
subsequently modified by written notice) and (a) if to the Company, with a copy
to Sonya F. Erickson, Venture Law Group, 4750 Carillon Point, Kirkland,
Washington 98033, fax number (425) 739-8750 or (b) if to the Purchasers, with a
copy to Richard Porter, Kirkland & Ellis, Aon Center, 200 East Randolph Drive
Chicago, Illinois 60601, fax number (312) 861-2200.

               8.3 COUNTERPARTS. This Second Addendum may be executed in any
number of counterparts, each of which may be executed by less than all of the
Additional Purchasers, each of which shall be enforceable against the parties
actually executing such counterparts, and all of which together shall constitute
one instrument.

                            [Signature page follows]

                                      -5-

<PAGE>   6

        The parties hereto have executed this Second Addendum as of the date
first set forth above.

                                  XCYTE THERAPIES, INC.

                                  By:
                                       ----------------------------------------
                                       Ron J. Berenson, Chief Executive Officer

                                  Address:  1124 Columbia Street, Suite 130
                                            Seattle, WA  98104
                                  Fax:      (206) 262-6200

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   7

                                     ADDITIONAL PURCHASERS:

                                     VECTOR FUND MANAGEMENT, L.P.

                                     By:
                                           -------------------------------------
                                     Name:
                                           -------------------------------------
                                                          (print)
                                     Title:
                                           -------------------------------------

                                     Address:  1751 Lake Cook Road, Suite 350
                                               Deerfield, IL  60015
                                               Attn:  Doug Reed, M.D.

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   8

                                       INITIAL SERIES D INVESTORS:

                                       MPM BIOVENTURES II, L.P.

                                       By:  MPM Asset Management II, L.P., its
                                            General Partner
                                       By:  MPM Asset Management II LLC, its
                                            General Partner

                                       By:
                                            ------------------------------------
                                       Name:
                                       Title:

                                       MPM BIOVENTURES II-QP, L.P.

                                       By:  MPM Asset Management II, L.P., its
                                            General Partner
                                       By:  MPM Asset Management II LLC, its
                                            General Partner

                                       By:
                                            ------------------------------------
                                       Name:
                                       Title:

                                       MPM BIOVENTURES GMBH & CO.
                                       PARALLEL-BETEILIGUNGS KG

                                       By:  MPM Asset Management II, L.P., its
                                            General Partner
                                       By:  MPM Asset Management II LLC, its
                                            General Partner

                                       By:
                                            ------------------------------------
                                       Name:
                                       Title:

                                       MPM ASSET MANAGEMENT INVESTORS 2000 B LLC

                                       By:
                                            ------------------------------------

                                       Name:
                                       Title:

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   9

                                       INITIAL SERIES D INVESTORS:

                                       ---------------------------------
                                       JOHN E. PARKEY

                                       Address:  Tredegar Investments
                                                 6501 Columbia Center
                                                 701 Fifth Avenue
                                                 Seattle, WA  98104

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   10

                                       INITIAL SERIES D INVESTORS:

                                       ---------------------------------
                                       NEIL RUZIC

                                       Address:  c/o Little Stirrup Cay
                                                 Research Limited
                                                 345 East Lake Front Drive
                                                 Beverly Shores, IN  46301

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   11

                                       INITIAL SERIES D INVESTORS:

                                       ARCH VENTURE FUND III, L.P.

                                       By:
                                              ----------------------------------
                                       Name:
                                              ----------------------------------
                                                           (print)
                                       Title:
                                              ----------------------------------

                                       Address:  1000 Second Avenue, Suite 3700
                                                 Seattle, WA  98104-1053
                                                 Attn:  Bob Nelsen

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   12

                                       INITIAL SERIES D INVESTORS:

                                       ---------------------------------
                                       JIM ROBERTS

                                       Address:  2540 Shoreland Drive South
                                                 Seattle, WA  98144

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   13

                                       INITIAL SERIES D INVESTORS:

                                       ---------------------------------
                                       MARK GROUDINE

                                       Address:  1142 20th Avenue East
                                                 Seattle, WA  98112

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   14

INITIAL SERIES D INVESTORS:

DLJ CAPITAL CORP.

By:
       -------------------------------------------
Name:
       -------------------------------------------
                      (print)
Title:
       -------------------------------------------

Address:  3000 Sand Hill Road, Bldg. 3, Suite 170
          Menlo Park, CA  94025

DLJ FIRST ESC, L.P.

By:
       -------------------------------------------
Name:
       -------------------------------------------
                      (print)
Title:
       -------------------------------------------

Address:  3000 Sand Hill Road, Bldg. 3, Suite 170
          Menlo Park, CA  94025

SPROUT CAPITAL VII, L.P.

By:
       -------------------------------------------
Name:
       -------------------------------------------
                      (print)
Title:
       -------------------------------------------

Address:  3000 Sand Hill Road, Bldg. 3, Suite 170
          Menlo Park, CA  94025

THE SPROUT CEO FUND, L.P.

By:
       -------------------------------------------
Name:
       -------------------------------------------
                      (print)
Title:
       -------------------------------------------

Address:  3000 Sand Hill Road, Bldg. 3, Suite 170
          Menlo Park, CA  94025

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   15

INITIAL SERIES D INVESTORS:

ARCH VENTURE FUND III, L.P.

By:
       -------------------------------------------
Name:
       -------------------------------------------
                      (print)
Title:
       -------------------------------------------

Address:  1000 Second Avenue, Suite 3700
          Seattle, WA  98104-1053
          Attn:  Bob Nelsen

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   16

INITIAL SERIES D INVESTORS:

ALTA CALIFORNIA PARTNERS, L.P.

By:
       -------------------------------------------
Name:
       -------------------------------------------
                      (print)
Title:
       -------------------------------------------

Address:  One Embarcadero Center, Suite 4050
          San Francisco, CA  94111
          Attn:  Jean Deleage

ALTA EMBARCADERO PARTNERS, LLC

By:
       -------------------------------------------
Name:
       -------------------------------------------
                      (print)
Title:
       -------------------------------------------

Address:  One Embarcadero Center, Suite 4050
          San Francisco, CA  94111
          Attn: Jean Deleage

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   17

INITIAL SERIES D INVESTORS:

------------------------------------
TGI FUND II, LC

Address:     6501 Columbia Center
             701 5th Avenue
             Seattle, WA 98104
             Attn:  Michael Beblo & Dave Maki

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   18

INITIAL SERIES D INVESTORS:

------------------------------------
FALCON TECHNOLOGY PARTNERS, L.P.

Address:     600 Dorset Road
             Devon, PA 19333
             Attn:  Jim Rathman

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   19

INITIAL SERIES D INVESTORS:

------------------------------------
VULCAN VENTURES, INC.

Address:     110 110th Avenue NE, Suite 550
             Bellevue, WA  98004
             Attn:  Ruth B. Kunath

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   20

INITIAL SERIES D INVESTORS:

------------------------------------
FLUKE CAPITAL MANAGEMENT, L.P.

Address:     11400 SE 6th Street, Suite 230
             Bellevue, WA  98004
             Attn:  Dennis Weston

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   21

INITIAL SERIES D INVESTORS:

------------------------------------
TOM ALBERG

Address:     c/o Madrona Investment Group
             1000 2nd Avenue
             Seattle, WA 98104

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   22

INITIAL SERIES D INVESTORS:

------------------------------------
MGN OPPORTUNITY GROUP LLC

Address:     The Norton Building
             801 Second Avenue, Suite 1300
             Seattle, WA 98104
             Attn:  Stephen Humphreys

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   23

INITIAL SERIES D INVESTORS:

------------------------------------
ARNOLD L. HOLM, JR.

Address:     Holm Construction Services
             310 3rd Avenue NE, Suite 103
             Issaquah, WA  98027

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   24

INITIAL SERIES D INVESTORS:

------------------------------------
HENRY JAMES

Address:     22420 North Dogwood Lane
             Woodway, WA 98020

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   25

INITIAL SERIES D INVESTORS:

------------------------------------
OKI ENTERPRISES, LLC

Address:     c/o Scott Oki
             10838 Main Street
             Bellevue, WA  98004

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   26

INITIAL SERIES D INVESTORS:

------------------------------------
VLG INVESTMENTS LLC

Address:     c/o Elias J. Blawie
             2800 Sand Hill Road
             Menlo Park, CA  94025

------------------------------------
VLG ASSOCIATES 2000

Address:     c/o Elias J. Blawie
             2800 Sand Hill Road
             Menlo Park, CA  94025

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   27

INITIAL SERIES D INVESTORS:

------------------------------------
SONYA F. ERICKSON

Address:     4750 Carillon Point
             Kirkland, WA  98033

                    SIGNATURE PAGE TO XCYTE THERAPIES, INC.
              SECOND ADDENDUM TO SERIES D STOCK PURCHASE AGREEMENT

<PAGE>   28

                                    EXHIBIT A

                        SCHEDULE OF ADDITIONAL PURCHASERS

<TABLE>
<CAPTION>
             NAME/ADDRESS               AMOUNT INVESTED   NUMBER OF SHARES       NUMBER OF       PURCHASE PRICE
                                                                              WARRANT SHARES      OF WARRANTS

<S>                                     <C>               <C>                 <C>                <C>
 VECTOR LATER-STAGE EQUITY FUND II,       $500,000.38          179,856            20,144             $20.14
 L.P.
 1751 Lake Cook Road, Suite 350
 Deerfield, IL  60015
 Attn:  Doug Reed, M.D.

 VECTOR LATER-STAGE EQUITY FUND II       $1,500,001.12         539,569            60,431             $60.44
 (QP), L.P.
 1751 Lake Cook Road, Suite 350
 Deerfield, IL  60015
 Attn:  Doug Reed, M.D.

                       TOTAL             $2,000,001.50         719,425            80,575             $80.58

</TABLE>

<PAGE>   29

                                    EXHIBIT B

                           INITIAL SERIES D INVESTORS

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS               NUMBER OF SERIES D          NUMBER OF WARRANT
                                        PREFERRED SHARES                  SHARES
<S>                                     <C>                         <C>
DLJ CAPITAL CORP.                             6,475                          725
3000 Sand Hill Road
Building Three, Suite 170
Menlo Park, CA  94025
Attn:  Bob Curry

DLJ FIRST ESC L.P.                           32,374                        3,625
3000 Sand Hill Road
Building Three, Suite 170
Menlo Park, CA  94025
Attn:  Bob Curry

SPROUT CAPITAL VII, L.P.                    281,622                       31,541
3000 Sand Hill Road
Building Three, Suite 170
Menlo Park, CA  94025
Attn:  Bob Curry

THE SPROUT CEO FUND, L.P.                     3,270                          366
3000 Sand Hill Road
Building Three, Suite 170
Menlo Park, CA  94025
Attn:  Bob Curry

ARCH VENTURE FUND III, L.P.                1,321,942                     148,056
1000 Second Avenue, Suite 3700
Seattle, WA  98104-1053
Attn:  Bob Nelsen

ALTA CALIFORNIA PARTNERS, L.P.               571,491                      64,006
One Embarcadero Center
Suite 4050
San Francisco, CA  94111
Attn: Jean Deleage
</TABLE>

<PAGE>   30

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS               NUMBER OF SERIES D          NUMBER OF WARRANT
                                        PREFERRED SHARES                  SHARES
<S>                                     <C>                         <C>
ALTA EMBARCADERO
PARTNERS, LLC                                13,056                        1,462
One Embarcadero Center
Suite 4050
San Francisco, CA  94111
Attn: Jean Deleage

TGI FUND II, LC                             286,022                       32,034
6501 Columbia Center
701 - 5th Avenue
Seattle, WA  98104
Attn:  Michael Beblo and
       Dave Maki

FALCON TECHNOLOGY PARTNERS, L.P.             95,341                       10,678
600 Dorset Road
Devon, PA  19333
Attn: Jim Rathman

VULCAN VENTURES INC.                        719,424                       80,575
110 110th Avenue, NE, Suite 550
Bellevue, WA  98004
Attn:  Ruth B. Kunath

FLUKE CAPITAL MANAGEMENT, L.P.               89,928                       10,071
11400 SE 6th Street, Suite 230
Bellevue, WA  98004
Attn:  Dennis Weston and
       Kevin Gabelein

TOM ALBERG                                  719,424                       80,575
c/o Madrona Investment Group
1000 2nd Avenue
Seattle, WA  98104

</TABLE>

<PAGE>   31

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS               NUMBER OF SERIES D          NUMBER OF WARRANT
                                        PREFERRED SHARES                  SHARES
<S>                                     <C>                         <C>
MGN OPPORTUNITY GROUP LLC
Matthew G. Norton Company
The Norton Building
801 Second Avenue, Suite 1300               359,712                       40,287
Seattle, WA  98104
Attn:  Stephen Humphreys

ARNOLD L. HOLM, JR.                          36,000                        4,032
Holm Construction Services
310 3rd Avenue NE, Suite 103
Issaquah, WA  98027

HENRY JAMES                                  89,928                       10,071
22420 North Dogwood Lane
Woodway, WA  98020

OKI ENTERPRISES, LLC                        359,712                       40,287
c/o Scott Oki
10838 Main Street
Bellevue, WA  98004

VLG INVESTMENTS LLC                          12,619                        1,413
c/o Elias J. Blawie
2800 Sand Hill Road
Menlo Park, CA 94025

VLG ASSOCIATES 2000                           1,770                          198
c/o Elias J. Blawie
2800 Sand Hill Road
Menlo Park, CA 94025

SONYA F. ERICKSON                             1,799                          201
4750 Carillon Point
Kirkland, WA 98033

MPM BIOVENTURES II, LP                      320,719                       35,921
One Cambridge Center
Cambridge, MA 02142

</TABLE>

<PAGE>   32

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS               NUMBER OF SERIES D          NUMBER OF WARRANT
                                        PREFERRED SHARES                  SHARES
<S>                                     <C>                         <C>
MPM BIOVENTURES II-QP, LP                 2,905,900                      325,460
One Cambridge Center
Cambridge, MA 02142

MPM BIOVENTURES GMBH & CO.                1,023,022                      114,578
PARALLEL-BETEILIGUNGS KG
One Cambridge Center
Cambridge, MA 02142

MPM ASSET MANAGEMENT INVESTORS 2000          66,906                        7,494
B LLC
One Cambridge Center
Cambridge, MA 02142

JOHN E. PARKEY                               17,986                        2,014
Tredegar Investments
6501 Columbia Center
701 Fifth Avenue
Seattle, WA  98104

NEIL RUZIC                                   17,986                        2,014
Little Stirrup Cay Research Ltd.
345 Each Lake Front Drive
Beverly Shores, IN  46301

JIM ROBERTS                                  17,986                        2,014
2540 Shoreland Drive South
Seattle, WA  98144

MARK GROUDINE                                17,986                        2,014
1142 20th Avenue East
Seattle, WA  98112

TOTAL                                     9,390,400                    1,051,712
</TABLE>

<PAGE>   33

                                    EXHIBIT C

                AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

                                (SEE TAB NO. 31)

<PAGE>   34

                                    EXHIBIT D

                             SCHEDULE OF EXCEPTIONS

<PAGE>   35

                                    EXHIBIT E

                              FORM OF LEGAL OPINION

                                (See Tab No. 11<PAGE>   1
                                                                   EXHIBIT 10.5

                              XCYTE THERAPIES, INC.

                 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

        This Amended and Restated Investor Rights Agreement (the "Agreement") is
effective as of May 25, 2000, by and among Xcyte Therapies, Inc., a Delaware
corporation (the "Company"), the investors listed on Schedule A attached hereto
(the "Investors"), Phoenix Leasing Incorporated and Robert Kingsbook.

                                    RECITALS

        A. The Company sold and issued to certain Investors (the "Series A
Holders") 6,334,212 shares of the Series A Preferred Stock of the Company on
August 28, 1996.

        B. In connection with the Company's merger with CellGenEx, Inc., dated
August 27, 1997, the Company issued 526,300 shares of Series A Preferred Stock
to holders of CellGenEx Preferred Stock.

        C. The Company sold and issued to certain Investors (the "Series B
Holders") 3,903,080 shares of the Series B Preferred Stock of the Company.

        D. The Company sold and issued to certain Investors (the "Series C
Holders") 7,185,630 shares of the Series C Preferred Stock of the Company.

        E. Pursuant to that certain Restated Investor Rights Agreement, dated as
of July 21, 1998, (the "Prior Rights Agreement") the Company granted to such
Series A Holders, Series B Holders and Series C Holders certain rights and the
Series A Holders, Series B Holders and Series C Holders entered into certain
covenants between themselves.

        F. Pursuant to that certain Series D Preferred Stock Purchase Agreement
of even date herewith (the "Series D Agreement"), the Company has agreed to sell
to certain Investors (the "Series D Holders") a total of up to 7,194,245 shares
of the Series D Preferred Stock of the Company and, as an inducement for the
Series D Holders to purchase such shares, the Company, the Series A Holders, the
Series B Holders and the Series C Holders have agreed to enter into this
Agreement to supersede, amend and restate the rights granted to and covenants
agreed by the Series A Holders, Series B Holders and Series C Holders in the
Prior Rights Agreement. All shares of Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are
referred to herein as the "Preferred Shares."

        All terms not otherwise defined herein shall have the same meaning as
set forth in the Series D Agreement.

        NOW THEREFORE, the parties hereby agree as follows:

<PAGE>   2

        1. Registration Rights.

               1.1 Definitions. For purposes of this Section 1:

                        (a) The term "Act" shall mean the Securities Act of
1933, as amended.

                        (b) The term "Form S-3" means such form under the Act as
in effect on the date hereof or any registration form under the Act subsequently
adopted by the Securities and Exchange Commission (the "SEC") which permits
inclusion or incorporation of substantial information by reference to other
documents filed by the Company with the SEC;

                        (c) The term "Holder" means any person owning or having
the right to acquire Registrable Securities or any assignee thereof in
accordance with Section 1.12 hereof;

                        (d) The term "Qualified Public Offering" shall mean an
underwritten public offering of shares of the Company's Common Stock at a public
offering price per share of not less than $4.00 (as adjusted for stock splits,
combinations or consolidations) with gross proceeds to the Company of not less
than $20,000,000 at the public offering price;

                        (e) The term "register", "registered," and
"registration" refer to a registration effected by preparing and filing a
registration statement or similar document in compliance with the Act, and the
declaration or ordering of effectiveness of such registration statement or
document;

                        (f) The term "registration expenses" shall mean all
expenses, except as otherwise stated below, incurred by the Company in complying
with Sections 1.2, 1.3 and 1.11 hereof, including, without limitation, all
registration, qualification and filing fees, printing expenses, escrow fees,
fees and disbursements of counsel for the Company, fees and disbursement of one
counsel to the Holders, blue sky fees and expenses, the expense of any special
audits incident to or required by any such registration (but excluding the
compensation of regular employees of the Company which shall be paid in any
event by the Company).

                        (g) The term "Registrable Securities" means (1) the
Common Stock issued upon conversion of the Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock or Series D Preferred Stock or any
Common Stock issued upon conversion of the Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock or Series D Preferred Stock issuable
upon the exercise of outstanding warrants to purchase such shares of Preferred
Stock, (2) up to 6,158 shares of Common Stock of the Company issued or issuable
upon conversion of the Series C Preferred Stock issued or issuable upon exercise
of that certain warrant issued to Phoenix Leasing Incorporated, (3) up to 6,157
shares of Common Stock of the Company issued or issuable upon conversion of the
Series C Preferred Stock issued or issuable upon exercise of that certain
warrant issued to Robert Kingsbook and (4) any Common Stock of the Company
issued as (or issuable upon the conversion or exercise of any warrant, right or
other security which is issued as) a dividend or other distribution with respect
to, or in exchange

                                      -2-

<PAGE>   3

for or in replacement of, such Preferred Stock or Common Stock, excluding in all
cases, however, (i) any Registrable Securities sold by a person in a transaction
in which such person's rights under this Section 1 are not assigned, or (ii) any
Registrable Securities sold to or through a broker or dealer or underwriter in a
public distribution or a public securities transaction; and

                        (h) The number of shares of "Registrable Securities then
outstanding" shall be determined by the number of shares of Common Stock
outstanding which are, and the number of shares of Common Stock issuable
pursuant to then exercisable or convertible securities which are, Registrable
Securities.

               1.2 Request for Registration.

                        (a) If the Company shall receive at any time after the
earlier of (i) August 15, 2002 or (ii) six (6) months after the effective date
of a Qualified Public Offering (other than a registration statement relating
either to the sale of securities to employees of the Company pursuant to a stock
option, stock purchase or similar plan or a SEC Rule 145 transaction), a written
request from the Holders of at least fifty percent (50%) of the Registrable
Securities then outstanding (including securities convertible into Registrable
Securities) that the Company file a registration statement under the Act
covering the registration of at least fifty percent (50%) of Registrable
Securities, or any lesser number of shares if the anticipated aggregate offering
price, net of underwriting discounts and commissions, would exceed $10,000,000,
then the Company shall, within ten (10) days of the receipt thereof, give
written notice of such request to all Holders and shall, subject to the
limitations of Section 1.2(b), effect as soon as practicable, and in any event
within ninety (90) days of the receipt of such request, the registration under
the Act of all Registrable Securities which the Holders request to be registered
within twenty (20) days of the mailing of such written notice by the Company;
provided, however, that the Company shall not be obligated to take any action to
effect any such registration, qualification or compliance pursuant to this
Section 1.2(a):

                                (i) During the period starting with the date
thirty (30) days prior to the Company's estimated date of filing of, and ending
on the date one hundred twenty (120) days immediately following the effective
date of, any registration statement pertaining to securities of the Company
(other than a registration of securities in a Rule 145 transaction or with
respect to an employee benefit plan), provided that the Company is actively
employing in good faith all reasonable efforts to cause such registration
statement to become effective;

                                (ii) After the Company has effected two such
registrations pursuant to this Section 1.2(a), and such registrations have been
declared or ordered effective; or

                                (iii) If the Company shall furnish to such
Holders a certificate signed by the President of the Company stating that in the
good faith judgment of the Board of Directors it would be seriously detrimental
to the Company or its stockholders for a registration statement to be filed at
such time, then the Company's obligation to use its best efforts to register,
qualify or comply under this Section 1.2(a) shall be deferred for a period not
to exceed ninety (90) days from the date of receipt of

                                      -3-

<PAGE>   4
written request from the Holders; provided, however, that the Company may not
utilize this right more than once in any twelve-month period.

                        (b) If the Holders initiating the registration request
hereunder (the "Initiating Holders") intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so
advise the Company as a part of their request made pursuant to this Section 1.2
and the Company shall include such information in the written notice referred to
in Section 1.2(a). In such event, the right of any Holder to include his
Registrable Securities in such registration shall be conditioned upon such
Holder's participation in such underwriting and the inclusion of such Holder's
Registrable Securities in the underwriting (unless otherwise mutually agreed by
a majority in interest of the Initiating Holders and such Holder) to the extent
provided herein. All Holders proposing to distribute their securities through
such underwriting shall (together with the Company as provided in Section
1.4(e)) enter into an underwriting agreement in customary form with the
underwriter or underwriters selected for such underwriting by a majority in
interest of the Initiating Holders and reasonably acceptable to the Company.
Notwithstanding any other provision of this Section 1.2, if the underwriter
advises the Initiating Holders in writing that marketing factors require a
limitation of the number of shares to be underwritten, then the Initiating
Holders shall so advise all Holders of Registrable Securities which would
otherwise be underwritten pursuant hereto, and the number of shares of
Registrable Securities that may be included in the underwriting shall be
allocated among all Holders thereof, including the Initiating Holders, in
proportion (as nearly as practicable) to the amount of Registrable Securities of
the Company owned by each Holder at the time of filing of such Registration
Statement. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares
allocated to any Holder to the nearest one hundred (100) shares.

               If any Holder of Registrable Securities disapproves of the terms
of the underwriting, such Holder may elect to withdraw therefrom by written
notice to the Company, the managing underwriter and the Initiating Holders. The
Registrable Securities and/or other securities so withdrawn shall also be
withdrawn from registration, and such Registrable Securities shall not be
transferred in a public distribution prior to one hundred eighty (180) days
after the effective date of such registration, or such other shorter period of
time as the underwriters may require.
 .

               1.3 Company Registration. If (but without any obligation to do
so) the Company proposes to register (including for this purpose a registration
effected by the Company for stockholders other than the Holders) any of its
stock or other securities under the Act in connection with the public offering
of such securities solely for cash (other than a registration relating solely to
the sale of securities to participants in a Company stock plan, or a
registration on any form which does not include substantially the same
information as would be required to be included in a registration statement
covering the sale of the Registrable Securities), the Company shall, at such
time, give each Holder written notice of such registration thirty (30) days
prior to such registration. Upon the written request of each Holder given within
twenty (20) days after mailing of written notice by the Company, the Company
shall, subject to

                                      -4-

<PAGE>   5

the provisions of Section 1.8, cause to be registered under the Act all of the
Registrable Securities that each such Holder has requested to be registered.

               1.4 Obligations of the Company. Whenever required under this
Section 1 to effect the registration of any Registrable Securities, the Company
shall, as expeditiously as reasonably possible:

                        (a) Prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use its best efforts
to cause such registration statement to become effective, and, upon the request
of the Holders of a majority of the Registrable Securities registered
thereunder, keep such registration statement effective for up to ninety (90)
days.

                        (b) Prepare and file with the SEC such amendments and
supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the
provisions of the Act with respect to the disposition of all securities covered
by such registration statement.

                        (c) Furnish to the Holders such numbers of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Act, and such other documents as they may reasonably request
in order to facilitate the disposition of Registrable Securities owned by them.

                        (d) Use its best efforts to register and qualify the
securities covered by such registration statement under such other securities or
Blue Sky laws of such jurisdictions as shall be reasonably requested by the
Holders, provided that the Company shall not be required in connection therewith
or as a condition thereto to qualify to do business or to file a general consent
to service of process in any such states or jurisdictions.

                        (e) In the event of any underwritten public offering,
enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the managing underwriter of such offering. Each Holder
participating in such underwriting shall also enter into and perform its
obligations under such an agreement provided that such underwriting agreement
shall not provide for indemnification or contribution obligations on the part of
the holders greater than the obligations set forth in Section 1.9.

                        (f) Notify each Holder of Registrable Securities covered
by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Act of the happening of any event as a result
of which the prospectus included in such registration statement, as then in
effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances then existing.

                        (g) Furnish, at the request of any Holder requesting
registration of Registrable Securities pursuant to this Section 1, on the date
that such Registrable Securities are delivered to the underwriters for sale in
connection with a registration pursuant to this Section 1, if such securities
are being sold through underwriters, or, if such securities are not being sold
through underwriters, on the

                                      -5-

<PAGE>   6

date that the registration statement with respect to such securities becomes
effective, (i) an opinion, dated such date, of the counsel representing the
Company for the purposes of such registration, in form and substance as is
customarily given to underwriters in an underwritten public offering, addressed
to the underwriters, if any, and to the Holders requesting registration of
Registrable Securities and (ii) if such offering is being underwritten, a letter
dated such date, from the independent certified public accountants of the
Company, in form and substance as is customarily given by independent certified
public accountants to underwriters in an underwritten public offering, addressed
to the underwriters.

               1.5 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 1 with
respect to the Registrable Securities of any selling Holder that such holder
shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be required to effect the registration of such Holder's Registrable
Securities.

               1.6 Expenses of Demand Registration. All expenses other than
underwriting discounts and commissions incurred in connection with the
registration, filing or qualification pursuant to Section 1.2, including all
registration, filing and qualification fees, printers' and accounting fees, fees
and disbursements of counsel for the Company, and the reasonable fees and
disbursements of one counsel for the selling Holders shall be borne by the
Company; provided, however, that the Company shall not be required to pay for
any expenses of any registration proceeding begun pursuant to Section 1.2 if the
registration request is subsequently withdrawn at the request of the Holders of
a majority of the Registrable Securities to be registered (in which case all
participating Holders shall bear such expenses), unless the Holders of a
majority of the Registrable Securities agree to forfeit their right to a demand
registration pursuant to Section 1.2; provided further, however, that if at the
time of such withdrawal, the Holders have learned of a material adverse change
in the condition, business, or prospects of the Company from that known to the
Holders at the time of their request, of which the Company had or should have
had knowledge at the time of the request, then the Holders shall not be required
to pay any of such expenses and shall retain their rights pursuant to Section
1.2.

               1.7 Expenses of Company Registration. The Company shall bear and
pay all expenses incurred in connection with any registration, filing or
qualification of Registrable Securities with respect to the registrations
pursuant to Section 1.3 for each Holder (which right may be assigned as provided
in Section 1.12), including all registration, filing, and qualification fees,
printers and accounting fees relating or apportionable thereto and the fees and
disbursements of one counsel for the selling Holders selected by them, but
excluding underwriting discounts and commissions relating to Registrable
Securities.

               1.8 Underwriting Requirements. In connection with any offering
involving an underwriting of shares being issued by the Company, the Company
shall not be required under Section 1.3 to include any of the Holders'
securities in such underwriting unless they accept the terms of the underwriting
as agreed upon between the Company and the underwriters selected by it, and then
only in such quantity as will not, in the opinion of the underwriters,
jeopardize the success of the offering by the Company; provided that such
underwriting agreement shall not provide for indemnification or

                                      -6-

<PAGE>   7

contribution obligations on the part of the Holders greater than the obligations
set forth in Section 1.9. If the total amount of securities, including
Registrable Securities requested by stockholders to be included in such
offering, exceeds the amount of securities sold (other than by the Company) that
the underwriters reasonably believe compatible with the success of the offering,
then the Company shall be required to include in the offering only that number
of such securities, including Registrable Securities, which the underwriters
believe will not jeopardize the success of the offering (the securities so
included to be apportioned pro rata among the selling stockholders according to
the total amount of securities entitled to be included therein owned by each
selling stockholder or in such other proportions as shall mutually be agreed to
by such selling stockholders), but in no event shall any shares being sold by a
stockholder exercising a demand registration right similar to that granted in
Section 1.2 be excluded from such offering. For purposes of apportionment, any
selling stockholder which is a Holder of Registrable Securities and which is a
partnership or corporation, the partners, retired partners and stockholders of
such Holder, or the estates and family members of any such partners and retired
partners and any trusts for the benefit of any of the foregoing persons shall be
deemed to be a single "selling stockholder", and any pro rata reduction with
respect to such "selling stockholder" shall be based upon the aggregate amount
of shares carrying registration rights owned by all entities and individuals
included in such "selling stockholder", as defined in this sentence. In no
event, shall the amount of securities of the selling Holders included in the
registration be reduced below thirty percent (30%) of the total amount of the
securities included in such registration unless such registration is the
Company's initial public offering and such registration does not include the
shares of any other selling stockholders, in which event any or all of the
Registrable Securities may be excluded if the underwriter makes the
determination described above. To facilitate the allocation of shares in
accordance with the above provisions, the Company may round the number of shares
allocated to any Holder to the nearest one hundred (100) shares.

        If any Holder or holder disapproves of the terms of any such
underwriting, such Holder or holder may elect to withdraw therefrom by written
notice to the Company and the managing underwriter. Any Registrable Securities
and/or securities excluded or withdrawn from such underwriting shall be
withdrawn from such registration, and shall not be transferred in a public
distribution prior to one hundred eighty (180) days after the effective date of
the registration statement relating thereto, or such other shorter period of
time as the underwriters may require.

               1.9 Indemnification. In the event any Registrable Securities are
included in a registration statement under this Section 1:

                        (a) To the extent permitted by law, the Company will
indemnify and hold harmless each Holder, any underwriter (as defined in the Act)
for such Holder and each person, if any, who controls such Holder or underwriter
within the meaning of the Act or the Securities Exchange Act of 1934, amended
(the "1934 Act"), against any losses, claims, damages, or liabilities (joint or
several) to which they may become subject under the Act, the 1934 Act or other
federal or state law, insofar as such losses, claims, damages, or liabilities
(or actions in respect thereof) arise out of or are based upon any of the
following statements, omissions or violations (collectively a "Violation"): (i)
any untrue statement or alleged untrue statement of a material fact contained in
such registration statement, including any preliminary prospectus or final
prospectus contained therein or any amendments or supplements

                                      -7-

<PAGE>   8

thereto, (ii) the omission or alleged omission to state therein a material fact
required to be stated therein, or necessary to make the statements therein not
misleading, or (iii) any violation or alleged violation by the Company of the
Act, the 1934 Act, any state securities law or any rule or regulation
promulgated under the Act, the 1934 Act or any state securities law; and the
Company will pay to each such Holder, underwriter or controlling person, as
incurred, any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability, or
action; provided, however, that the indemnity agreement contained in this
Section 1.9(a) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability, or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld), nor
shall the Company be liable in any such case for any such loss, claim, damage,
liability, or action to the extent that it arises out of or is based upon a
Violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by
any such Holder, underwriter or controlling person.

                        (b) To the extent permitted by law, each selling Holder
will indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each person, if any, who
controls the Company within the meaning of the Act, any underwriter, any other
Holder selling securities in such registration statement and any controlling
person of any such underwriter or other Holder, against any losses, claims,
damages, or liabilities (joint or several) to which any of the foregoing persons
may become subject, under the Act, the 1934 Act or other federal or state law,
insofar as such losses, claims, damages, or liabilities (or actions in respect
thereto) arise out of or are based upon any Violation, in each case to the
extent (and only to the extent) that such Violation occurs in reliance upon and
in conformity with written information furnished by such Holder expressly for
use in connection with such registration; and each such Holder will pay, as
incurred, any legal or other expenses reasonably incurred by any person intended
to be indemnified pursuant to this Section 1.9(b), in connection with
investigating or defending any such loss, claim, damage, liability, or action;
provided, however, that the indemnity agreement contained in this Section 1.9(b)
shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of the
Holder, which consent shall not be unreasonably withheld; provided, that, in no
event shall any indemnity under this Section 1.9(b) exceed the gross proceeds
from the offering received by such Holder, unless such liability resulted from
the willful misconduct of such Holder.

                        (c) Promptly after receipt by an indemnified party under
this Section 1.9 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 1.9, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party shall
have the right to retain its own counsel, with the fees and expenses to be paid
by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other
party represented by such counsel in such proceeding. The failure to deliver
written notice to the indemnifying party within a

                                      -8-

<PAGE>   9

reasonable time of the commencement of any such action, if prejudicial to its
ability to defend such action, shall relieve such indemnifying party of any
liability to the indemnified party under this Section 1.9(c), but the omission
to so deliver written notice to the indemnifying party will not relieve it of
any liability that it may have to any indemnified party otherwise than under
this Section 1.9.

                        (d) If the indemnification provided for in this Section
1.9 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage, or expense
referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by
such indemnified party as a result of such loss, liability, claim, damage, or
expense in such proportion as is appropriate to reflect the relative fault of
the indemnifying party on the one hand and of the indemnified party on the other
in connection with the statements or omissions that resulted in such loss,
liability, claim, damage, or expense as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative intent,
knowledge and access to information.

                        (e) The obligations of the Company and Holders under
this Section 1.9 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 1, and otherwise.

               1.10 Reports Under Securities Exchange Act of 1934. With a view
to making available to the Holders the benefits of Rule 144 promulgated under
the Act and any other rule or regulation of the SEC that may at any time permit
a Holder to sell securities of the Company to the public without registration or
pursuant to a registration on Form S-3, the Company agrees to:

                        (a) make and keep public information available, as those
terms are understood and defined in SEC Rule 144, at all times after ninety (90)
days after the effective date of the first registration statement filed by the
Company for the offering of its securities to the general public;

                        (b) take such action, including the voluntary
registration of its Common Stock under Section 12 of the 1934 Act, as is
necessary to enable the Holders to utilize Form S-3 for the sale of their
Registrable Securities, such action to be taken as soon as practicable after the
end of the fiscal year in which the first registration statement filed by the
Company for the offering of its securities to the general public is declared
effective;

                        (c) file with the SEC in a timely manner all reports and
other documents required of the Company under the Act and the 1934 Act; and

                        (d) furnish to any Holder, so long as the Holder owns
any Registrable Securities, forthwith upon request (i) a written statement by
the Company that it has complied with the reporting requirements of SEC Rule 144
(at any time after ninety (90) days after the effective date of the

                                      -9-

<PAGE>   10

first registration statement filed by the Company), the Act and the 1934 Act (at
any time after it has become subject to such reporting requirements), or that it
qualifies as a registrant whose securities may be resold pursuant to Form S-3
(at any time after it so qualifies), (ii) a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by
the Company, and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC which permits the
selling of any such securities without registration or pursuant to such form.

               1.11 Form S-3 Registration.

                        (a) In case the Company shall receive from any Holder or
Holders a written request or requests that the Company effect a registration on
Form S-3 and any related qualification or compliance with respect to all or a
part of the Registrable Securities owned by such Holder or Holders, the Company
will:

                                (i) promptly give written notice of the proposed
registration, and any related qualification or compliance, to all other Holders;
and

                                (ii) as soon as practicable, effect such
registration and all such qualifications and compliances as may be so requested
and as would permit or facilitate the sale and distribution of all or such
portion of such Holder's or Holders' Registrable Securities as are specified in
such request, together with all or such portion of the Registrable Securities of
any other Holder or Holders joining in such request as are specified in a
written request given within 15 days after receipt of such written notice from
the Company; provided, however, that the Company shall not be obligated to
effect any such registration, qualification or compliance, pursuant to this
Section 1.11: (1) if Form S-3 is not available for such offering by the Holders;
(2) if the Holders, together with the holders of any other securities of the
Company entitled to inclusion in such registration, propose to sell Registrable
Securities and such other securities (if any) at an aggregate price to the
public (net of any underwriters' discounts or commissions) of less than
$500,000; (3) if the Company shall furnish to the Holders a certificate signed
by the President of the Company stating that in the good faith judgment of the
Board of Directors of the Company, it would be seriously detrimental to the
Company and its stockholders for such Form S-3 Registration to be effected at
such time, in which event the Company shall have the right to defer the filing
of the Form S-3 registration statement for a period of not more than 120 days
after receipt of the request of the Holder or Holders under this Section 1.11;
provided, however, that the Company shall not utilize this right more than once
in any twelve (12) month period; (4) if the Company has already effected one
registration on Form S-3 within the past twelve (12) months for the Holders
pursuant to this Section 1.11; (5) in any particular jurisdiction in which the
Company would be required to qualify to do business or to execute a general
consent to service of process in effecting such registration, qualification or
compliance; (6) if the Company, within ten (10) days of the receipt of the
request of the initiating Holders, gives notice of its bona fide intention to
effect the filing of a registration statement with the Commission within ninety
(90) days of receipt of such request (other than with respect to a registration
statement relating to a Rule 145 transaction, or an offering solely to
employees); or (7) during the period starting with the date ninety (90) days
prior to the Company's estimated date of filing of, and ending on

                                      -10-

<PAGE>   11

the date six (6) months immediately following, the effective date of any
registration statement pertaining to securities of the Company (other than a
registration of securities in a Rule 145 transaction or with respect to an
employee benefit plan), provided that the Company is actively employing in good
faith all reasonable efforts to cause such registration statement to become
effective.

                        (b) If the Initiating Holders requesting such
registration hereunder intend to distribute the Registrable Securities covered
by their request by means of an underwriting, they shall so advise the Company
as part of their request made pursuant to this Section 1.11 and the Company
shall include such information in the written notice referred to in Section
1.11(a)(i). In such event, the right of any Holder to include his Registrable
Securities in such registration shall be conditioned upon such Holder's
participation in such underwriting and the inclusion of such Holder's
Registrable Securities in the underwriting (unless otherwise mutually agreed by
a majority in interest of the Initiating Holders and such Holder) to the extent
provided herein. All Holders proposing to distribute their securities through
such underwriting shall (together with the Company as provided in Section
1.4(e)) enter into an underwriting agreement in customary form with the
underwriter or underwriters selected for such underwriting by a majority in
interest of the Initiating Holders and reasonably acceptable to the Company.
Notwithstanding any other provision of this Section 1.11, if the underwriter
advises the Initiating Holders in writing that marketing factors require a
limitation of the number of shares to be underwritten, then the Initiating
Holders shall so advise all Holders of Registrable Securities which would
otherwise be underwritten pursuant hereto, and the number of shares of
Registrable Securities that may be included in the underwriting shall be
allocated among all Holders thereof, including the Initiating Holders, in
proportion (as nearly as practicable) to the amount of Registrable Securities of
the Company owned by each Holder. To facilitate the allocation of shares in
accordance with the above provisions, the Company may round the number of shares
allocated to any Holder to the nearest one hundred (100) shares.

        If any Holder or holder disapproves of the terms of any such
underwriting, such Holder or holder may elect to withdraw therefrom by written
notice to the Company and the managing underwriter. Any Registrable Securities
and/or securities excluded or withdrawn from such underwriting shall be
withdrawn from such registration, and shall not be transferred in a public
distribution prior to one hundred eighty (180) days after the effective date of
the registration statement relating thereto, or such other shorter period of
time as the underwriters may require.

                        (c) Subject to the foregoing, the Company shall file a
registration statement covering the Registrable Securities and other securities
so requested to be registered as soon as practicable after receipt of the
request or requests of the Holders. All expenses incurred in connection with a
registration requested pursuant to Section 1.11, including all registration,
filing, qualification, printer's and accounting fees and the reasonable fees and
disbursements of one counsel for the selling Holders selected by them, but
excluding any underwriters' discounts or commissions associated with Registrable
Securities, shall be borne by the Company. Registrations effected pursuant to
this Section 1.11 shall not be counted as demands for registration or
registrations effected pursuant to Section 1.2 or 1.3, respectively.

               1.12 Assignment of Registration Rights. The rights to cause the
Company to

                                      -11-

<PAGE>   12

register Registrable Securities pursuant to this Section 1 may be assigned by a
Holder to a transferee or assignee who acquires at least the lesser of all of
the shares owned by such Holder or 500,000 shares of Registrable Securities,
provided the Company is, within a reasonable time after such transfer, furnished
with written notice of the name and address of such transferee or assignee and
the securities with respect to which such registration rights are being
assigned; and provided, further, that such assignment shall be effective only if
immediately following such transfer the further disposition of such securities
by the transferee or assignee is restricted under the Act. Notwithstanding the
above, such rights may be assigned by a Holder to an Affiliate (as defined
below) of such Holder (the "Transferee"), regardless of the number of shares
acquired by such Transferee. For purposes of this Agreement, "Affiliate"
includes, with respect to a party which is a partnership or limited liability
company, its partners, members or an affiliated entity managed by the same
manager or managing partner or management company, or managed or owned by an
entity controlling, controlled by, or under common control with, such manager or
managing partner or management company.

               1.13 Limitations on Subsequent Registration Rights. From and
after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of at least two-thirds (66-2/3%) of the
outstanding Registrable Securities, enter into any agreement with any holder or
prospective holder of any securities of the Company which would allow such
holder or prospective holder to include such securities in any registration
filed under Section 1.3 hereof, unless (i) under the terms of such agreement,
such holder or prospective holder may include such securities in any such
registration only to the extent that the inclusion of its securities will not
reduce the amount of the Registrable Securities of the Holders which is included
or (ii) the Board of Directors approves the grant of registration right to such
holder or prospective holder.

               1.14 "Market Stand-Off" Agreement. Each holder of securities
which are or at one time were Registrable Securities (or which are or were
convertible into Registrable Securities) hereby agrees that, during a period not
to exceed one hundred eighty (180) days, following the effective date of a
registration statement of the Company filed under the Act, it shall not, to the
extent requested by the Company and such underwriter, sell or otherwise transfer
or dispose of (other than to a donee who agrees to be similarly bound), make a
short sale, loan, or grant any option for the purchase of any Common Stock or
other securities of the Company held by it at any time during such period except
Common Stock included in such registration; provided, however, that:

                        (a) such agreement shall be applicable only to the first
such registration statement of the Company which covers Common Stock (or other
securities) to be sold on its behalf to the public in an underwritten offering;
and

                        (b) all officers and directors of the Company enter into
similar agreements.

        In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to the Registrable Securities of each
Investor (and the shares or securities of every other person subject to the
foregoing restriction) until the end of such period and, furthermore, each
holder of

                                      -12-

<PAGE>   13

securities agrees to execute all documents effectuating the above as may be
requested by the underwriter at the time of the initial public offering.

               1.15 Termination of Registration Rights. No stockholder shall be
entitled to exercise any right provided for in this Section 1 after five (5)
years following the Company's first Qualified Public Offering.

        2. Preemptive Rights.

               2.1 Grant of Right. Subject to the terms and conditions specified
in this Section 2, the Company hereby grants to each Investor who, together with
its Affiliates, holds more than 500,000 shares of Preferred Stock a preemptive
right with respect to future sales by the Company of its Future Shares (as
hereinafter defined).

               2.2 Future Shares. "Future Shares" shall mean shares of any
capital stock of the Company, whether now authorized or not, and any rights,
options or warrants to purchase such capital stock, and securities of any type
that are, or may become, convertible into such capital stock; provided however,
that "Future Shares" do not include (i) the Shares purchased under the Series D
Stock Purchase Agreement (ii) the shares of Common Stock issued or issuable upon
the conversion of the Preferred Stock, (iii) securities offered pursuant to a
registration statement filed under the Act, (iv) securities issued pursuant to
the acquisition of another corporation by the Company by merger or, purchase of
substantially all of the assets or other reorganization, (v) securities issued
in connection with or as consideration for a collaborative partnership
arrangement, as approved by a majority of the Board of Directors of the Company,
or the acquisition, leasing or licensing of technology or other significant
assets to be used in the Company's business, as approved by a majority of the
Board of Directors of the Company and (vi) securities issued or issuable to
officers, directors, employees or consultants of the Company pursuant to any
employee or consultant stock offering, plan or arrangement approved by a
majority of the Board of Directors of the Company.

               2.3 Notice. In the event the Company proposes to offer any of its
Future Shares, the Company shall first make an offering of such Future Shares to
each Investor in accordance with the following provisions:

                        (a) The Company shall deliver a notice by certified mail
(the "Notice") to the Investors stating (i) its bona fide intention to offer
such Future Shares, (ii) the number of such Future Shares to be offered, (iii)
the price, if any, for which it proposes to offer such Future Shares, and (iv) a
statement as to the number of days from receipt of such Notice within which the
Investor must respond to such Notice.

                        (b) Within twenty (20) calendar days after receipt of
the Notice, the Investor may elect to purchase or obtain, at the price and on
the terms specified in the Notice, up to that portion of such Future Shares
which equals the proportion that the number of shares of Common Stock issued and
held, or issuable upon conversion of the Shares then held, by such Investor
bears to the total

                                      -13-

<PAGE>   14

number of shares of Common Stock issued and outstanding, including shares
issuable upon conversion of convertible securities issued and outstanding. If an
Investor elects not to purchase such shares up to its pro rata allocation, any
affiliate of such Investor which is also an Investor may increase its allocation
to add the pro rata shares not purchased by its affiliate. The Company shall
promptly, in writing, inform each Investor which purchases all of the Future
Shares available to it (the "Fully-Exercising Investor") of any other Investor's
failure to do likewise. During the ten (10) day period commencing after receipt
of such information, each Fully-Exercising Investor shall be entitled to obtain
that portion of the Future Shares offered to the Investors which was not
subscribed for, which is equal to the proportion that the number of shares of
Common Stock issued and held, or issuable upon conversion of the Shares then
held, by such Fully-Exercising Investor bears to the total number of shares of
Common Stock issued and outstanding, including shares issuable upon conversion
of convertible securities issued and outstanding then held, by all
Fully-Exercising Investors who wish to purchase some of the unsubscribed shares.

               2.4 Sale after Notice. If all such Future Shares referred to in
the Notice are not elected to be obtained as provided in Section 2.3 hereof, the
Company may, during the 90-day period following the expiration of the period
provided in Section 2.3 hereof, offer the remaining unsubscribed Future Shares
to any person or persons at a price not less than, and upon terms no more
favorable to the offeree than those specified in the Notice. If the Company does
not enter into an agreement for the sale of the Future Shares within such
period, or if such agreement is not consummated within 90 days of the execution
thereof, the right provided hereunder shall be deemed to be revived and such
Future Shares shall not be offered unless first reoffered to the Investors in
accordance herewith.

               2.5 Assignment. The right of first offer granted under this
Section 2 is assignable by the Investors to any transferee who acquires at least
the lesser of all of the shares owned by such Investor or a minimum of 500,000
shares of Common Stock (including any shares of Common Stock into which shares
of Preferred Stock are convertible).

               2.6 Termination of Rights. No stockholder shall be entitled to
exercise any right provided for in this Section 2 (i) upon the consummation of
the sale of securities pursuant to a registration statement filed by the Company
under the Act in connection with the initial firm commitment underwritten
offering of its securities to the general public or (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d)
of the Securities Exchange Act of 1934, whichever event shall first occur.

        3. Voting Provisions. The undersigned hereby agree that in all elections
of directors of the Company the Investors will vote their shares such that one
nominee designated by Alta Venture Partners, one nominee designated by the
Sprout Group, one nominee designated by ARCH Venture Fund III, L.P., and one
nominee designated by TGI Fund II will be elected to the Company's Board of
Directors. This Section 3 shall automatically terminate upon the earlier to
occur of: (i) a Qualified Public Offering or (ii) when the Company first becomes
subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the
Securities Exchange Act of 1934, as amended.

                                      -14-

<PAGE>   15

        4. Prior Rights Agreements. Effective upon the execution of this
Agreement by the Company and at least the holders of two-thirds (66 2/3%) of the
Registrable Securities under the Prior Rights Agreement, the Prior Rights
Agreement is null and void and superseded in its entirety by this Agreement.

        5. Waiver of Preemptive Rights. To the extent that an Investor under the
Prior Rights Agreement is not purchasing its pro rata share of Series D
Preferred Stock pursuant to the Series D Agreement, all rights under the
Preemptive Rights set forth in Section 2 of the Prior Rights Agreement to
purchase such securities and to receive notice is hereby waived. This waiver is
effective upon the execution of this Agreement by the holders of a majority of
the Registrable Securities under the Prior Rights Agreement.

        6. Transferability.

               6.1 Restrictions on Transferability. The Shares and the
Registrable Securities shall not be sold, assigned, transferred or pledged
except upon the conditions specified in this Section 6, which conditions are
intended to ensure compliance with the provisions of the Securities Act. The
Investors will cause any proposed purchaser, assignee, transferee, or pledgee of
the Shares or the Registrable Securities held by the Investors to agree to take
and hold such securities subject to the provisions and upon the conditions
specified in this Section 6.

               6.2 Restrictive Legend. Each certificate representing (i) the
Shares, (ii) the Registrable Securities and (iii) any other securities issued in
respect of the Shares or the Registrable Securities upon any stock split, stock
dividend, recapitalization, merger, consolidation or similar event, shall
(unless otherwise permitted by the provisions of Section 6.3 below) be stamped
or otherwise imprinted with a legend in the following form (in addition to any
legend required under applicable state securities laws):

               "THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
               ACT OF 1933, AS AMENDED (THE "ACT"). THEY MAY NOT BE SOLD,
               OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A
               REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES
               UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE
               COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD
               PURSUANT TO RULE 144 OF SUCH ACT. THESE SECURITIES ARE SUBJECT TO
               A CERTAIN VOTING PROVISION ENTERED INTO BY AND AMONG THE
               INVESTORS."

               The Investors and Holders consent to the Company making a
notation on its records and giving instructions to any transfer agent of the
Shares or the Registrable Securities in order to implement the restrictions on
transfer established in this Section 6.

                                      -15-

<PAGE>   16

               6.3 Notice of Proposed Transfers. The holder of each certificate
representing Restricted Securities by acceptance thereof agrees to comply in all
respects with the provisions of this Section 6.3. Prior to any proposed sale,
assignment, transfer or pledge of any Restricted Securities (other than (i) a
transfer not involving a change in beneficial ownership, or (ii) in transactions
involving the distribution without consideration of Restricted Securities by the
Investors to any of its partners, or retired partners, or to the estate of any
of its partners or retired partners, (iii) a transfer to an affiliated fund,
partnership or company, which is not a competitor of the Company, or a transfer
to an Affiliate of the holder, subject to compliance with applicable securities
laws, or (iv) transfers in compliance with Rule 144, so long as the Company is
furnished with satisfactory evidence of compliance with such Rule), unless there
is in effect a registration statement under the Securities Act covering the
proposed transfer, the holder thereof shall give written notice to the Company
of such holder's intention to effect such transfer, sale, assignment or pledge.
Each such notice shall describe the manner and circumstances of the proposed
transfer, sale, assignment or pledge in sufficient detail, and shall be
accompanied, at such holder's expense by either (a) a written opinion of legal
counsel who shall, and whose legal opinion shall, be reasonably satisfactory to
the Company addressed to the Company, to the effect that the proposed transfer
of the Restricted Securities may be effected without registration under the
Securities Act, or (b) a "no action" letter from the Commission to the effect
that the transfer of such securities without registration will not result in a
recommendation by the staff of the Commission that action be taken with respect
thereto, whereupon the holder of such Restricted Securities shall be entitled to
transfer such Restricted Securities in accordance with the terms of the notice
delivered by the holder to the Company. Each certificate evidencing the
Restricted Securities transferred as above provided shall bear, except if such
transfer is made pursuant to Rule 144, the appropriate restrictive legend set
forth in Section 6.2 above, except that such certificate shall not bear such
restrictive legend if in the opinion of counsel for such holder and in the
reasonable opinion of the Company such legend is not required in order to
establish compliance with any provision of the Securities Act.

               6.4 Removal of Restrictions on Transfer of Securities. Any legend
referred to in Section 6.2 hereof stamped on a certificate evidencing (i) the
Shares, (ii) the Registrable Securities or (iii) any other securities issued in
respect of the Shares or the Registrable Securities upon any stock split, stock
dividend, recapitalization, merger, consolidation or similar event and the stock
transfer instructions and record notations with respect to such security shall
be removed and the Company shall issue a certificate without such legend to the
holder of such security if such security is registered under the Securities Act,
or if such holder provides the Company with an opinion of counsel (which may be
counsel for the Company) reasonably acceptable to the Company to the effect that
a public sale or transfer of such security may be made without registration
under the Securities Act or such holder provides the Company with reasonable
assurances, which may, at the option of the Company, include an opinion of
counsel satisfactory to the Company, that such security can be sold pursuant to
Section (k) of Rule 144 under the Securities Act.

        7. Covenants of the Company.

               7.1 Delivery of Financial Statements. The Company shall deliver
to each Investor who holds, together with its Affiliates, an aggregate of
500,000 shares of Series C Preferred Stock or

                                      -16-

<PAGE>   17

Series D Preferred Stock (or Conversion Shares) (a "Major Investor") and upon
such Major Investors timely request for each such report:

                        (a) as soon as practicable, but in any event within one
hundred eighty (180) days after the end of each fiscal year of the Company,
statements of operations and cash flow for such fiscal year, a balance sheet of
the Company as of the end of such year, and a schedule as to the sources and
applications of funds for such year, such year-end financial reports to be in
reasonable detail, prepared in accordance with generally accepted accounting
principles ("GAAP"), and audited and certified by independent public accountants
of nationally recognized standing selected by the Company;

                        (b) as soon as practicable, but in any event prior to
the end of each fiscal year of the Company, an annual budget and plan of
operations for the upcoming fiscal year approved by the Board of Directors;

                        (c) within twenty (20) days of the end of each month,
and until a public offering of Common Stock of the Company, an unaudited
statement of operations and balance sheet for and as of the end of such month,
in reasonable detail and prepared in accordance with GAAP, subject to year end
audit adjustments and the absence of footnotes;

                        (d) with respect to the financial statements called for
in subsection (c) of this Section 7.1, an instrument executed by the Chief
Financial Officer or President of the Company and certifying that such
financials were prepared in accordance with GAAP consistently applied with prior
practice for earlier periods and fairly present the financial condition of the
Company and its results of operation for the period specified, subject to
year-end audit adjustments and the absence of footnotes;

                        (e) all accounting letters or reports from independent
auditors and such other information relating to the financial condition,
business, prospects or corporate affairs of the Company as the Major Investor or
any assignee of the Major Investor may from time to time request, provided,
however, that the Company shall not be obligated to provide information which
the Board of Directors deems in good faith to be proprietary; and

               7.2 Confidential Information. Each Major Investor agrees that it
will keep confidential and will not disclose any confidential, proprietary or
secret information which such Major Investor may obtain from the Company, and
which the Company has prominently marked "confidential", "proprietary" or
"secret" or has otherwise identified as being such, orally or in writing,
pursuant to financial statements, reports and other materials submitted by the
Company as required hereunder, unless such information is or becomes known to
the Major Investor from a source other than the Company without violation of any
rights of the Company, or is or becomes publicly known, or unless the Company
gives its written consent to the Major Investor's release of such information,
except that no such written consent shall be required (and the Major Investor
shall be free to release such information to such recipient) if such information
is to be provided to a Major Investor's counsel, in response to a subpoena or
regulatory inquiry, or to an officer, director or partner of a Major Investor,
provided that the Major

                                      -17-

<PAGE>   18

Investor shall inform the recipient of the confidential nature of such
information, and such recipient must agree in advance of disclosure to treat the
information as confidential.

               7.3 Inspection. The Company shall permit each Major Investor, at
such Major Investor's expense, to visit and inspect the Company's properties, to
examine its books of account and records and to discuss the Company's affairs,
finances and accounts with its officers, all at such reasonable times as may be
requested by the Major Investor; provided, however, that the Company shall not
be obligated pursuant to this Section 7.3 to provide access to any information
which the Board of Directors reasonably considers to be a trade secret or
similar confidential information.

               7.4 Board Visitation Rights. Each Major Investor or its
designated representative, unless already represented on the Company's Board of
Directors (the "Observer"), shall have the right to attend the Company's Board
of Directors meetings and to receive, at the same time such information as is
provided to its directors and notice and copies of all information furnished to
directors in connection with all meetings of the Board of Directors; provided,
however, that the Company shall not be obligated pursuant to this Section 7.4 to
provide access to any information which the Company's Board of Directors
reasonably considers to be a trade secret or similar confidential information
unless the Observer executes a form of nondisclosure agreement acceptable to the
Company, which acceptance shall not be unreasonably withheld. The rights of the
Major Investor under this Section 7.4 shall not be transferable.

               7.5 Termination of Covenants. The covenants set forth in Sections
7.1, and 7.2 shall terminate as to Investors and be of no further force or
effect upon the earlier to occur of: (i) a Qualified Public Offering or (ii)
when the Company first becomes subject to the periodic reporting requirements of
Sections 12(g) or 15(d) of the Securities Exchange Act of 1934, as amended.

        8. Miscellaneous Provisions.

               8.1 Waivers and Amendments. Any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or
prospectively), only with the written consent of the Company and the holders of
at least a majority of the shares of Registrable Securities except that any such
amendment of Sections 1.13, 3 or 8.1 shall require the written consent of the
Company and the holders of at least two-thirds (66 2/3%) of the shares of
Registrable Securities. Any amendment or waiver effected in accordance with this
Section 8.1 shall be binding upon each person or entity which are granted
certain rights under this Agreement and the Company. Notwithstanding the
foregoing, the Company may, without obtaining any further consent of the holders
of Registrable Securities, amend this Agreement to the extent necessary to grant
rights and obligations on a pari passu basis with the rights and obligations of
the Series D Investors hereunder to investors in any subsequent round of
financing prior to the Subsequent Closing Date (as such term is defined in the
Series D Stock Purchase Agreement), and such investors shall become parties to
this Agreement by executing a counterpart hereof.

                                      -18-

<PAGE>   19

               8.2 Notices. All notices and other communications required or
permitted hereunder shall be in writing and, except as otherwise noted herein,
shall be deemed effectively given upon personal delivery, refusal of delivery,
delivery by nationally recognized courier or five business days after deposit
with the United States Post Office (by first class mail, postage prepaid),
addressed: (a) if to the Company, at 1124 Columbia Street, Suite 130, Seattle,
WA 98104 (or at such other address as the Company shall have furnished to the
Investors in writing) attention of President and (b) if to an Investor, at the
latest address of such person shown on the Company's records.

               8.3 Descriptive Headings. The descriptive headings herein have
been inserted for convenience only and shall not be deemed to limit or otherwise
affect the construction of any provisions hereof.

               8.4 Governing Law. This Agreement shall be governed by and
interpreted under the laws of the State of Washington as applied to agreements
among Washington residents, made and to be performed entirely within the State
of Washington.

               8.5 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall for all purposes be deemed to be an original
and all of which shall constitute the same instrument, but only one of which
need be produced.

               8.6 Expenses. If any action at law or in equity is necessary to
enforce or interpret the terms of this Agreement, the prevailing party shall be
entitled to reasonable attorney's fees, costs and necessary disbursements in
addition to any other relief to which such party may be entitled.

               8.7 Successors and Assigns. Except as otherwise expressly
provided in this Agreement, this Agreement shall benefit and bind the
successors, assigns, heirs, executors and administrators of the parties to this
Agreement.

               8.8 Entire Agreement. This Agreement constitutes the entire
agreement among the parties hereto with respect to the specific subject matter
hereof.

               8.9 Separability; Severability. Unless expressly provided in this
Agreement, the rights of each Investor under this Agreement are several rights,
not rights jointly held with any other Investors. Any invalidity, illegality or
limitation on the enforceability of this Agreement with respect to any Investor
shall not affect the validity, legality or enforceability of this Agreement with
respect to the other Investors. If any provision of this Agreement is judicially
determined to be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not be affected or impaired.

               8.10 Stock Splits. All references to numbers of shares in this
Agreement shall be appropriately adjusted to reflect any stock dividend, split,
combination or other recapitalization of shares by the Company occurring after
the date of this Agreement.

                                      -19-

<PAGE>   20

        IN WITNESS WHEREOF, the parties have executed this Agreement on the day
and year first set forth above.

COMPANY:                                        INVESTORS:

XCYTE THERAPIES, INC.                           --------------------------------
                                                (Investor)

                                                By:
                                                    ----------------------------
By:                                             Name:
     ----------------------------                     --------------------------
                                                               (print)
Title:                                          Title:
      ---------------------------                      -------------------------

FOUNDERS:

---------------------------------
Ronald J. Berenson

---------------------------------
Jeffrey Bluestone

---------------------------------
Carl June

---------------------------------
Jeffrey Ledbetter

---------------------------------
Craig Thompson

                    [SIGNATURE PAGE FOR XCYTE THERAPIES, INC.
                 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT]

<PAGE>   21

                                   SCHEDULE A

                              SCHEDULE OF INVESTORS

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS                    SERIES A      SERIES B      SERIES C      SERIES D
<S>                                          <C>           <C>           <C>           <C>
Alta California Partners, L.P.               1,840,086      787,294       949,635       571,491
One Embarcadero Center
Suite 4050
San Francisco, CA  94111
Attn: Elaine Walker and Jean Deleage
Tel:  (415) 362-4022
Fax:  (415) 362-6178

Alta Embarcadero Partners, LLC                 54,651        17,987        21,696        13,056
One Embarcadero Center
Suite 4050
San Francisco, CA  94111
Attn: Elaine Walker and Jean Deleage
Tel:  (415) 362-4022
Fax:  (415) 362-6178

ARCH Venture Fund II, L.P.                    631,579       363,636          0             0
8735 West Higgins Road
Suite 235
Chicago, IL  60631
Attn:  Melanie Davis
Tel: (773) 380-6600
Fax: (773) 380-6606
1000 Second Avenue, Suite 3700
Seattle, WA  98104-1053
Attn:  Bob Nelsen

Ron Berenson, M.D.                             57,895          0             0             0
PO Box 1598
Mercer Island, WA  98040
Tel:  (206) 232-1433
Fax:  (206) 236-1876
</TABLE>

<PAGE>   22

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS                    SERIES A      SERIES B      SERIES C      SERIES D
<S>                                          <C>           <C>           <C>           <C>
                                               26,316          0             0             0
GC&H Investments
1 Maritime Plaza, 20th Fl.
San Francisco, CA 94111
Attn:  John L. Cordoza
Tel: (415) 693-2600

CV Sofinnova Venture Partners III
140 Geary Street, 10th Floor                  947,368       338,289        59,880          0
San Francisco, CA 94108
Attn.: Michael F. Powell
Tel:  (415) 228-3387
Fax:  (415) 228-3390

DLJ Capital Corp.                              52,632        10,909        22,859        6,475
3000 Sand Hill Road
Bldg. 3, Ste. 170
Menlo Park, CA  94025
Tel:  (650) 234-2700
Fax:  (650) 234-2779
Attn:  Bob Curry

DLJ First ESC L.P.                            263,158        54,545       114,294        32,374
3000 Sand Hill Road
Bldg. 3, Ste. 170
Menlo Park, CA  94025
Tel:  (650) 234-2700
Fax:  (650) 234-2779
Attn:  Bob Curry

Sprout Capital VII, L.P.                     2,289,197      474,488       994,235       281,622
3000 Sand Hill Road
Bldg. 3, Ste. 170
Menlo Park, CA  94025
Tel:  (650) 234-2700
Fax:  (650) 234-2779
Attn:  Bob Curry

The Sprout CEO Fund, L.P.                      26,592        5,512         11,549        3,270
3000 Sand Hill Road
Bldg. 3, Ste. 170
Menlo Park, CA  94025
Tel:  (650) 234-2700
Fax:  (650) 234-2779
Attn:  Bob Curry
</TABLE>

<PAGE>   23

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS                    SERIES A      SERIES B      SERIES C      SERIES D
<S>                                          <C>           <C>           <C>           <C>
WS Investment Company                          26,316          0             0             0
650 Page Mill Road
Palo Alto, CA  94304
Tel:  (650) 443-9300
Fax:  (650) 845-5000
Attn:  J. Casey McGlynn

Paul Etsekson                                  26,316          0             0             0
Fleet Pride
P.O. Box 80986
Seattle, WA 98108
Tel: (206) 654-8089
Fax:  (206) 343-1499

Gary P. Farber IRA Rollover                    26,316          0             0             0
Summit Partners
16102 S.E. Cougar Mountain Way
Bellevue, WA 98006
Tel: (206) 447-9020

Mrs. Thomas Georges, Jr.                       26,316          0             0             0
1814 S.W. Jackson Street
Portland, OR 97201
Tel: (503) 227-3898

Thomas Georges, Jr.                            10,526          0             0             0
1814 S.W. Jackson Street
Portland, OR 97201
Tel: (503) 227-3898

Michael S. Rabson                              2,632           0             0             0
c/o  Maxygen, Inc.
515 Galveston Drive
Redwood City, CA 94063

SMS                                              0           22,727          0             0
Bader Martin Ross & Smith, P.S.
1000 Second Avenue, 34th Floor
Seattle, WA  98104
Tel: (206) 667-0310
Fax: (206) 682-1874
Attn:  Walter R. Smith, CPA
</TABLE>

<PAGE>   24

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS                    SERIES A      SERIES B      SERIES C      SERIES D
<S>                                          <C>           <C>           <C>           <C>
Benjamin Stern
528 Laidlaw Blvd
Winnipeg, Canada                               26,316          0             0             0
R3POK9

ARCH Development Corporation                  157,890          0             0             0
Walker 213
1101 East 58th Street
Chicago, IL  60637
Attn:  Terry Willey

ARCH Venture Fund III, L.P.                   157,890      1,681,818     1,119,265      962,230
8735 West Higgins Road
Suite 235
Chicago, IL  60631
Attn:  Melanie Davis
Tel: (773) 380-6600
Fax: (773) 380-6606
1000 Second Avenue, Suite 3700
Seattle, WA  98104-1053
Attn: Bob Nelsen

Jeffrey Ledbetter                             157,890          0             0             0
18798 Ridgefield Road NW
Shoreline, WA  98177

TGI Fund II, LC                                  0             0         1,796,410      286,022
6501 Columbia Center
701-5th Avenue
Seattle, WA  98104
Attn:  Michael Beblo and Dave Maki

Vengott LC                                       0             0          179,641          0
6501 Columbia Center
701-5th Avenue
Seattle, WA  98104
Attn:  Michael Beblo and Dave Maki

Steven M. Johnson                                0             0           32,934          0
6501 Columbia Center
701-5th Avenue
Seattle, WA  98104
</TABLE>

<PAGE>   25

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS                    SERIES A      SERIES B      SERIES C      SERIES D
<S>                                          <C>           <C>           <C>           <C>
John E. Parkey                                   0             0           29,940          0
6501 Columbia Center
701-5th Avenue
Seattle, WA  98104

Charles A. Blanchard                             0             0           14,970          0
6501 Columbia Center
701-5th Avenue
Seattle, WA  98104

Anthony P. Russo, Trustee                        0             0           14,970          0
Anthony P. Russo Separate Property Trust
U/A 9/11/90
6501 Columbia Center
701-5th Avenue
Seattle, WA  98104

David J. Maki                                    0             0           14,970          0
Tredegar Investments
6300 Columbia Center
701 Fifth Avenue
Seattle, WA  98104-7092

R. Ray Cummings                                  0             0           11,976          0
Cummings Consulting
8695 NE Grizdale Lane
Bainbridge Island, WA  98110

Falcon Technology Partners, L.P.                 0             0          598,802        95,341
600 Dorset Road
Devon, PA  19333
Attn:  Jim Rathman

Vulcan Ventures Inc.                             0             0          598,802       719,424
110 110th Avenue NE, Suite 550
Bellevue, WA  98004
Attn:  Ruth B. Kunath

Fluke Capital Management, L.P.                   0             0          598,802        89,928
11400 SE  6th Street, Suite 230
Bellevue, WA  98004
Attn:  Dennis P. Weston & Kevin C.
Gabelein
</TABLE>

<PAGE>   26

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS                    SERIES A      SERIES B      SERIES C      SERIES D
<S>                                          <C>           <C>           <C>           <C>
Tom Alberg                                       0             0             0          719,424
Madrona Investment Group
1000 Second Avenue
Seattle, WA  98104

MGN Opportunity Group LLC                        0             0             0          359,712
Matthew G. Norton Company
The Norton Building
801 Second Avenue, Suite 1300
Seattle, WA  98104
Attn:  Stephen Humphreys

Arnold L. Holm, Jr.                              0             0             0           36,000
Holm Construction Services
310 Third Avenue NE, Suite 103
Issaquah, WA  98027

Henry James                                      0             0             0           89,928
22420 North Dogwood Lane
Woodway, WA  98020

Scott Oki                                        0             0             0          359,712
Oki Enterprises, LLC
10838 Main Street
Bellevue, WA  98004

VLG Investments LLC                              0             0             0           12,619
2800 Sand Hill Road
Menlo Park, CA  94025
Attn:  Elias J. Blawie

VLG Associates 2000                              0             0             0           1,770
2800 Sand Hill Road
Menlo Park, CA  94025
Attn:  Elias J. Blawie

Sonya F. Erickson                                0             0             0           1,799
4750 Carillon Point
Kirkland, WA  98033

Marilyn Parsons                                52,630          0             0             0
306 NW 113th Place
Seattle, WA  98177
</TABLE>

<PAGE>   27

<TABLE>
<CAPTION>
INVESTOR NAME AND ADDRESS                    SERIES A      SERIES B      SERIES C      SERIES D
<S>                                          <C>           <C>           <C>           <C>
Genetics Institute                               0          145,875          0             0
c/o American Home Products Corp.
S Giralda Farms
Madison, NJ  07940
Attn:  Senior V.P. & General Counsel
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]